New findings could lead to more growth from their prized medicines.As two of the most-watched and fastest-growing big pharma companies, Novo Nordisk (NVO 1.53%) and Eli Lilly (LLY 2.10%) already have upwardly mobile stock prices.And now, there's yet another piece of news that could presage even more growth over the long term. Let's explore this new development. This clinical trial could pave the way for even larger marketsNovo Nordisk's blockbuster drug Ozempic is widely known for being effective at control ...

Things are going exactly as planned for the biotech giant.The battle for leadership in the anti-obesity drug market is heating up. Eli Lilly (LLY 2.10%) and Novo Nordisk are the two undisputed frontrunners, but many other drugmakers are looking to challenge the status quo. Novo Nordisk's Wegovy, first approved in the U.S. in 2021, has been growing its sales rapidly.However, Eli Lilly launched a competing product, Zepbound, late last year. Analysts have incredibly high hopes for Zepbound, and the medicine ha ...

Viking shares have soared recently on optimism about its program.Eli Lilly (LLY 1.57%) and Novo Nordisk (NVO 0.42%) have seen their revenue soar in recent times thanks to their weight loss drugs. The companies sell products that target key hormones involved in the regulation of blood sugar levels and appetite, and they've proven their efficacy in clinical trials and the real world.All of this has helped the companies' shares soar to record highs, and considering demand for these products, the gains may be f ...

ToplineZepound—an Eli Lilly-produced drug that has become a popular alternative to other weight loss drugs such as Wegovy and Ozempic—is facing a shortage in the U.S. of some of its doses because of the growing demand for the drug, according to a warning from the Food and Drug Administration issued Wednesday.The FDA confirmed there was a shortage of some doses of the weight loss drug on Wednesday. AP/Darron Cummings Key FactsOf the six different doses of injectable Zepbound pens approved by the FDA and sold ...

What has been the top-performing stock so far of 2024?If you had said server installer Super Micro Computer (NASDAQ:SMCI), that would be a great answer. Louis Navellier’s AI bet has surged 260% this year over AI excitement. Sezzle (NASDAQ:SEZL) would have been an even better response. This fintech startup has risen 280% since January.But among large companies, the biggest winner has been Viking Therapeutics (NASDAQ:VKTX), a firm that’s surged 360% since the start of the year. The company is developing a new ...

Bear markets come and go, but history has taught investors time and time again that bull markets not only tend to outlast these periods, but eventually drive stocks higher than before the downturn hit. Both bull and bear markets can present opportunities for the long-term investor who is focusing on buying great businesses, and not just share prices.If you have cash to put to work, it's always a good time to add to or start positions in quality businesses with wide moats and compelling long-term growth stor ...

DNY59/iStock via Getty Images Investment Overview- Background To Stunning Rise Of GLP-1 Analogue Drug Class Doubtless, readers will be familiar with the Wegovy / Zepbound, Ozempic / Mounjaro, tirzepatide / semaglutide "miracle" weight loss story by now - but to recap: Semaglutide is a glucagon-like peptide-1 receptor agonist, or "GLP-1" agonist / analogue developed by Danish Pharma Novo Nordisk (NVO). These types of drugs have been used for many years to treat type 2 diabetes, as they prompt the body to ...

Siarhei Khaletski/iStock via Getty Images The biggest pharmaceutical stock by market capitalisation, Eli Lilly (NYSE:LLY) continues its unabated upward journey. Not only has it more than doubled its price in the past year, but it’s up by 33.6% in the first quarter of 2024 (Q1 2024) as well. Here I look at whether there's more upside to it, especially as its market multiples are looking rather stretched now. Winning in the Diabetes market The company's gains in its diabetes segments certainly give room f ...

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.Demand for weight loss drugs is booming in the U.S. despite their limited insurance coverage and roughly $1,000 monthly price tags before discounts. But some patients are willing to pay more out of pocket for those treatments than others — and that desire is strongly correlated to their annual income.That's according to a recent survey from Evercore ISI focused on GLP-1s, a new class of medications used to treat Typ ...

Scott Olson/Getty Images News Context The world of software is being revolutionized by AI technology. The same thing happens in the pharmaceutical world, where new drugs to fight obesity are the driver of its transformation. It is a revolutionary medicine not only to get people thinner but also because obesity is the cause of a lot of diseases, from cardiovascular health problems to diabetes and cancer… Two companies are leading this space: Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY). I am interested in ...